Loading clinical trials...

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

NCT07275359•Duke University

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 65 and older
•History of COPD defined by spirometry demonstrating FEV1/FVC \< 70%
•10 or more tobacco pack year history
•History of frequent exacerbations defined as: 1 severe (i.e., COPD hospitalization) or 2 moderate (i.e., outpatient treated exacerbations) in the previous 12 months

Exclusion Criteria

•Diabetes or actively being treated with metformin
•Metformin allergy
•History of lactic acidosis not explained by acute, severe illness
•History of low vitamin B12 levels and unwilling to begin standard of care treatment for low vitamin B12 levels
•Hepatic impairment defined as history of cirrhosis or abnormal liver function tests (e.g., alanine transaminase (ALT): 7-55 units per liter (U/L), aspartate transaminase (AST): 8-48 U/L, alkaline phosphatase (ALP): 40-129 U/L, or bilirubin: 0.1-1.2 milligrams per deciliter (mg/dL))
•Renal impairment defined as eGFR \< 60 mL/min/1.73m2
•Cognitive impairment
•Dementia
•Heart failure with reduced ejection fraction \< 50%
•Alcohol use disorder
+3 more criteria

Locations (1)

Duke Asthma, Allergy, and Airway Center

Durham, North Carolina, United States

Key Dates

Start Date

March 1, 2026

Primary Completion Date

March 31, 2027

Completion Date

September 30, 2027

Last Updated

December 10, 2025

Enrollment

ESTIMATED participants

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Metformin

DRUG

Contacts

Christopher Mosher, MD

CONTACT

(919) 684-8111 christopher.mosher@duke.edu

Jessica Shier

CONTACT

(919) 684-9139 jessica.shier@duke.edu

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease

NCT07382258

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

Mindful-Breath for People With COPD

NCT07195838

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease

Mindful-Breath for People With COPD

The HELlenic Thoracic Society Initiative for CΟPD and CVD

Magnetic Stimulation of Diaphragm in Chronic Obstructive Pulmonary Disease

COPD Exacerbation Modelling Using Unobtrusive Sensors - the TOLIFE Clinical Study A